

# One-Pot Acid-Catalyzed Ring-Opening/Cyclization/Oxidation of Aziridines with *N*-Tosylhydrazones: Access to 1,2,4-Triazines


Lorène Crespin,<sup>\*,†</sup> Lorenzo Biancalana,<sup>†</sup> Tobias Morack,<sup>†</sup> David C. Blakemore,<sup>‡</sup> and Steven V. Ley<sup>†</sup>

<sup>†</sup>Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, U.K.

<sup>‡</sup>Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States

**S** Supporting Information

**ABSTRACT:** A new, three-step, telescoped reaction sequence for the regioselective conversion of *N*-tosyl hydrazones and aziridines to 3,6-disubstituted and 3,5,6-trisubstituted 1,2,4-triazines is described. The process involves an efficient nucleophilic ring opening of the aziridine, giving access to a wide range of aminohydrazones, isolated with excellent yields. A “one-pot” procedure, combining the ring opening with a cyclization and an oxidation step, allows the preparation of diversified triazines in good yields.




1,2,4-Triazine derivatives represent an important class of nitrogen heterocycles: they possess a wide range of applications from ligands for transition-metal complexes<sup>1</sup> to agrochemistry<sup>2</sup> and medicine. They have been shown to exhibit a broad spectrum of biological activities with anti-inflammatory,<sup>3</sup> antitumor,<sup>4</sup> antibacterial,<sup>5</sup> anticonvulsant,<sup>6</sup> and antiviral<sup>7</sup> properties being reported. They are also widely used as key synthetic building blocks for the preparation of heterocyclic systems via hetero-Diels–Alder cycloadditions.<sup>8</sup>

To date, the main methods for the preparation of 1,2,4-triazines include two types of bond formation: the construction of the  $N^1-C^6/N^4-C^5$  bonds between 1,2-diketones and amidrazones leads to 3,5-disubstituted or 3,5,6-trisubstituted 1,2,4-triazines<sup>9</sup> while the reaction between 2 equiv of acid hydrazides and  $\beta$ -halogeno ketones forms 3,6-disubstituted triazines.<sup>10</sup> These disubstituted compounds are also accessible via the formation of the  $N^2-C^3/N^4-C^3$  bonds from the addition of an oxime hydrazone and an aldehyde.<sup>11</sup> More recently, other methods have emerged using diazo compounds or domino annulation reactions.<sup>12</sup> Despite the formation of triazines being well studied in recent decades, new and versatile strategies to construct the 1,2,4-triazine core are still of high interest for both fragment-based drug discovery and synthetic chemistry programs. The synthesis of trisubstituted triazines bearing different substituents on the C5- and C6-positions still remains problematic with the current use of unsymmetrical diketones often producing a mixture of regioisomers.<sup>9d,g</sup> Moreover, an analysis of internally synthesized compounds in the Pfizer file showed that only 17% of triazines made have different substituents on the C5- and C6-positions, reinforcing the challenge in accessing this substitution pattern.

In light of the above comments, we report a conceptually new pathway using a double disconnection  $N^1-C^6/N^4-C^3$  for the preparation of 1,2,4-triazines. It was envisaged that this

## Scheme 1. Pathways for the Preparation of 1,2,4-Triazines




approach would allow the formation of 3,6-disubstituted and 3,5,6-trisubstituted triazines via a three-step, “one-pot” procedure, starting with a Lewis acid catalyzed *N*-alkylation of *N*-tosyl hydrazones 1 with aziridines 2. The cyclization of the intermediate 3 followed by a double elimination of the tosyl groups would afford the dihydrotriazine 4, which upon oxidation would form the corresponding 1,2,4-triazine 5 (Scheme 1).

Received: January 12, 2017

Published: February 15, 2017

Although an aminohydrazone close to **3** has been observed once as an intermediate in an aerobic copper-catalyzed tandem reaction involving tosyl hydrazones and aziridines by the Wang group,<sup>13</sup> to the best of our knowledge, acid-catalyzed *N*-alkylation of *N*-tosyl hydrazones with aziridines has never been reported previously.<sup>14</sup> This observation encouraged us to explore the ring opening of aziridines more closely to find suitable conditions to prepare aminohydrazones **3**, a class of novel molecules whose chemistry remains mostly unknown. The optimization process was attempted with two readily accessible compounds: the phenyl tosyl hydrazone **1a** and the phenyl tosylaziridine **2a** (Table 1). Mixing of the two reactants

**Table 1. Optimization of the Ring Opening of Aziridine 1a with *N*-Tosylhydrazone 2a**




entry	aziridine (equiv)	BF <sub>3</sub> ·OEt <sub>2</sub> (equiv)	solvent	reaction time (h)	yield <sup>a</sup> (%)
1	1.5		CH <sub>2</sub> Cl <sub>2</sub>	24	0 <sup>b</sup>
2	1.5	1.5	CH <sub>2</sub> Cl <sub>2</sub>	24	37
3	1.5	0.2	CH <sub>2</sub> Cl <sub>2</sub>	1	90
4	1.5	0.2	THF	1	<sup>c</sup>
5	1.5	0.2	toluene	1	70 <sup>d</sup>
6	1.5	0.2	Et <sub>2</sub> O	1	40 <sup>d</sup>
7	1.2	0.2	CH <sub>2</sub> Cl <sub>2</sub>	1	91

<sup>a</sup>Isolated yields reported unless stated otherwise. <sup>b</sup>No reaction. <sup>c</sup>Polymerization was observed. <sup>d</sup>Percent conversion of starting material.

in CH<sub>2</sub>Cl<sub>2</sub> resulted in clean recovery of starting materials only (Table 1, entry 1). A screen of Lewis acids revealed that BF<sub>3</sub>·OEt<sub>2</sub> was the most suitable, and in the presence of a stoichiometric amount, the reaction led to 37% of the intermediate **3a** after 24 h, with a significant amount of decomposition in the crude being observed (Table 1, entry 2). By lowering the reaction time to 1 h and using a catalytic amount of BF<sub>3</sub>·OEt<sub>2</sub>, a significant increase in yield to 90% was noted (Table 1, entry 3). A solvent screen showed that CH<sub>2</sub>Cl<sub>2</sub> was the solvent of choice as the reaction proceeded with incomplete conversion in both toluene and Et<sub>2</sub>O (Table 1, entries 5 and 6), while THF afforded polymerization (Table 1, entry 4). Finally, it was found that reducing the amount of aziridine to 1.2 equiv resulted in a 91% yield of the desired product **3a** (Table 1, entry 7).

Under the optimized conditions, we next investigated the scope of the reaction (Scheme 2). A wide range of tosyl hydrazones **1** reacted with phenylaziridine and led to the amino hydrazones **3** in excellent yields. Hydrazones bearing both electron-donating and electron-withdrawing aryl substituents (**3a–i**) were tolerated, and steric hindrance at the *ortho*-position led to only a small decrease in yield (**3j**). Electron-rich heteroaryls such as thiophene or furan were also suitable substrates (**3l,m**). The only limitation found was the incompatibility of the Lewis acid with electron-rich amines: *N*-methylindole or pyridine hydrazones were unreactive toward the reaction conditions. This restriction could be partially overturned by the use of an electron-withdrawing functionality on the nitrogen atom: acetylindole hydrazone gave **3k** in excellent yield. Alkyl hydrazones also reacted under the

**Scheme 2. Scope of the Ring-Opening Reaction<sup>a</sup>**



<sup>a</sup>Conditions: **1** (0.2 mmol), **2** (1.2 equiv), BF<sub>3</sub>·OEt<sub>2</sub> (0.2 equiv), CH<sub>2</sub>Cl<sub>2</sub> (0.2 M), rt, 1–2 h. <sup>b</sup>Reaction performed with BF<sub>3</sub>·THF instead of BF<sub>3</sub>·OEt<sub>2</sub>. <sup>c</sup>Product unstable to column chromatography, yield from the crude. <sup>d</sup>dr = 50:50. <sup>e</sup>dr = 78:22. <sup>f</sup>Product **3x** observed by mass, unstable to purification or any other analysis.


standard conditions with moderate yields (**3n,o**). Replacement of BF<sub>3</sub>·OEt<sub>2</sub> with the safer reagent BF<sub>3</sub>·THF was also possible, resulting in similar yields.<sup>15</sup> Further investigations using various *N*-tosylaziridines **2** were then carried out: monosubstituted aziridines proceeded very smoothly (**3p–s**), while disubstituted aziridines led to a mixture of diastereoisomers, isolated in excellent combined yields, with a single regioisomer being observed (**3t–w**). Moreover, the aziridine presenting a complex steroid structure was found to be a suitable partner, leading to **3y** in 84% yield. The regioselectivity of the ring-opening of the aziridine was confirmed by X-ray crystallography for product **3b** (see the SI).<sup>16</sup>

With these excellent initial results in hand, a three step, “one-pot” procedure was attempted. The second step consisted of the cyclization of the aminohydrazones **3** and the elimination of both tosyl groups, requiring an excess of a base. This step was found to be very dependent on both solvent and the nature of the base, with the reaction occurring only in toluene at 110 °C in the presence of cesium carbonate.

With the objective of avoiding the isolation of the dihydrotriazines **4**, activated manganese dioxide was chosen as the oxidant for its compatibility with the cyclization conditions step and was used together with cesium carbonate to afford directly the 1,2,4-triazines **5** after 3 h at 110 °C in toluene in a sealed tube (see the SI for the full discussion of the optimization).

With the optimized conditions established, a wide range of 3,6-disubstituted and 3,5,6-trisubstituted 1,2,4-triazines were prepared with moderate to good yields (up to 66%) for the telescoped process (Scheme 3). The reaction could be easily

Scheme 3. Scope for the Preparation of Triazines 5<sup>a</sup>




<sup>a</sup>Conditions: 1) **1** (0.5 mmol), **2** (1.2 equiv), BF<sub>3</sub>·OEt<sub>2</sub> (0.2 equiv), CH<sub>2</sub>Cl<sub>2</sub> (0.2 M), rt, 1–2 h. 2) Cs<sub>2</sub>CO<sub>3</sub> (3.5 equiv), MnO<sub>2</sub> (12 equiv), toluene (0.1 M), 110 °C, 3 h, sealed tube. <sup>b</sup>Reaction carried out under reflux in toluene instead of a sealed tube. <sup>c</sup>5 mmol scale. <sup>d</sup>The BPin-substituted triazine was oxidized to the corresponding alcohol before isolation. <sup>e</sup>Cs<sub>2</sub>CO<sub>3</sub> (5 equiv), MnO<sub>2</sub> (16 equiv). <sup>f</sup>Overoxidation *in situ* by MnO<sub>2</sub>.

scaled (5 mmol) with no significant change in the yield (**5h**). Electron-withdrawing, halogeno-substituted aryls and CF<sub>3</sub> hydrazones led to the desired triazines in yields between 34% and 60%. Substrates with electron-donating substituted aryls or sterically hindered hydrazones tended to react in a lower yield (**5f,j**) while the unactivated hydrazone **1o** formed

the product **5o** in only 8% yield. We were delighted that the useful Bpin functionality was tolerated under the reaction conditions (**5i**), allowing further elaboration of the product through cross-coupling reactions.<sup>17</sup> Heteroaryl hydrazones gave the triazines in good yields, and in the case of the indole, the acetyl nitrogen was deprotected *in situ* due to the basic conditions of the reaction (**5k–m**). Monosubstituted aziridines were also suitable partners to afford 1,2,4-triazines **5p–s**. In particular, the sterically hindered mesityl substituent was tolerated (**5q**). Moreover, the natural product-derived triazine **5y** was formed efficiently. Two fused triazines could also be prepared (**5t,u**) and isolated in their oxidized form. One of the benefits of the “one-pot” procedure was the opportunity to synthesize triazines such as **5x** whose corresponding intermediate **3x** was too unstable to be isolated. Finally, although the formation of the trisubstituted triazines is currently limited to alkyl groups on the C5-position (**5v–x**) in low to moderate yields, this methodology offers access to complex trisubstituted triazines as single regioisomers. Therefore, our approach compares favorably with the methods using 1,2-diketones which lead to regioisomeric mixtures. The 3,5,6-trisubstituted triazine scaffold can also be easily accessed via a nucleophilic addition/oxidation process on the synthesized 3,6-disubstituted triazines.<sup>18</sup>

Mechanistically, we believe that the aziridine is activated by the Lewis acid and the hydrazone acts as a nucleophile to effect the ring opening. This ring opening is known to occur selectively via a C–N bond cleavage, and the nucleophile only attacks at the benzylic position, leading to the single observed regioisomer **3**.<sup>19</sup> Next, compound **3** is deprotonated, and thermal activation allows the closure the 6-membered ring, followed by the successive elimination of the two tosyl groups to form the dihydrotriazine **4**, for which the structure is confirmed spectroscopically (see the SI). The intermediate from the monoelimination of the tosyl group can also be observed when the reaction is performed at 80 °C, where no second elimination occurs. To end the sequence, oxidation of the dihydrotriazine with MnO<sub>2</sub> affords the desired 1,2,4-triazines (Scheme 4).

Scheme 4. Plausible Mechanism for the Synthesis of Triazines



In conclusion, we have reported a new method to access the 1,2,4-triazine scaffold via a three-step, telescoped reaction sequence using *N*-tosyl hydrazones and aziridines. This approach represents a complementary alternative to well-known procedures and affords the 3,6-disubstituted and 3,5,6-trisubstituted 1,2,4-triazines in a regioselective manner. The diverse library of triazines synthesized by this route generates 15 previously unknown structures as potentially useful compounds for both medicinal and agrochemical applications.

**■ ASSOCIATED CONTENT****■ Supporting Information**

The Supporting Information is available free of charge on the ACS Publications website at DOI: [10.1021/acs.orglett.7b00101](https://doi.org/10.1021/acs.orglett.7b00101).

Crystallographic data for **3b** (CIF)

Experimental procedures, compound characterization data, and NMR spectra for all compounds (PDF)

**■ AUTHOR INFORMATION****Corresponding Author**

\*E-mail: [lc667@cam.ac.uk](mailto:lc667@cam.ac.uk).

**ORCID**

Lorène Crespin: 0000-0002-7491-7538

Steven V. Ley: 0000-0002-7816-0042

**Notes**

The authors declare no competing financial interest.

Additional data related to this publication is available at the University of Cambridge Institutional Data Repository (<https://doi.org/10.17863/CAM.7001>).

**■ ACKNOWLEDGMENTS**

This work was supported by a postdoctoral fellowship from Pfizer (L.C.) and EPSRC Grant Nos. EP/K009494/1 and EP/M004120/1 (S.V.L.). We also thank Dr. Andrew D. Bond for conducting X-ray crystallographic analysis.

**■ REFERENCES**

(1) For recent examples, see: (a) Hudson, M. J.; Boucher, C. E.; Braekers, D.; Desreux, J. F.; Drew, M. G. B.; Foreman, M. R. St J.; Harwood, L. M.; Hill, C.; Madic, C.; Marken, F.; Youngs, T. G. A. *New J. Chem.* **2006**, *30*, 1171. (b) Wolińska, E. *Tetrahedron* **2013**, *69*, 7269. (c) Marandi, F.; Jangholi, M.; Hakimi, M.; Rudbari, H. A.; Bruno, G. J. *Mol. Struct.* **2013**, *1036*, 71. (d) Guillet, G. L.; Hyatt, I. F. D.; Hillesheim, P. C.; Abboud, K. A.; Scott, M. J. *New J. Chem.* **2013**, *37*, 119. (e) Coogan, N. T.; Chimes, M. A.; Raftery, J.; Mocilac, P.; Denecke, M. A. *J. Org. Chem.* **2015**, *80*, 8684. (f) Lewis, F. W.; Harwood, L. M.; Hudson, M. J.; Geist, A.; Kozhevnikov, V. N.; Distler, P.; John, J. *Chem. Sci.* **2015**, *6*, 4812.

(2) Braun, R.; Waldraff, C.; Dietrich, H.; Gatzweiler, E.; Rosinger, C. H.; Schmutzler, D. *PCT Int. Appl.* **2014**, WO 2014053473 A1, Apr 10, 2014.

(3) Khoshneviszadeh, M.; Ghahremani, M. H.; Foroumadi, A.; Miri, R.; Firuzi, O.; Madadkar-Sobhani, A.; Edraki, N.; Parsa, M.; Shafiee, A. *Bioorg. Med. Chem.* **2013**, *21*, 6708.

(4) (a) Yurttaş, L.; Demirayak, S.; Ilgin, S.; Atli, O. *Bioorg. Med. Chem.* **2014**, *22*, 6313. (b) Karczmarzyk, Z.; Wysocki, W.; Urbańczyk-Lipkowska, Z.; Kalicki, P.; Bielawska, A.; Bielawski, K.; Ławecka, J. *Chem. Pharm. Bull.* **2015**, *63*, 531.

(5) For example, naturally occurring antibiotics fervenulin and toxoflavin contain the 1,2,4-triazine moiety. See also: (a) Sztanke, K.; Pasternak, K.; Rajtar, B.; Sztanke, M.; Majek, M.; Polz-Daciewicz, M. *Bioorg. Med. Chem.* **2007**, *15*, 5480. (b) Culakova, H.; Dzugasova, V.; Gbelska, Y.; Subik, J. *Microbiol. Res.* **2013**, *168*, 147.

(6) For example, the 1,2,4-triazine core can be found in Lamictal, an anti-epileptic medication produced by GlaxoSmithKline. See also: Mallikarjuna, B. P.; Suresh Kumar, G. V.; Sastry, B. S.; Nagaraj; Manohara, K. P. *J. Zhejiang Univ., Sci., B* **2007**, *8*, 526.

(7) Rusinov, V. L.; Egorov, I. N.; Chupakhin, O. N.; Belanov, E. F.; Bormotov, N. I.; Serova, O. A. *Pharm. Chem. J.* **2012**, *45*, 655.

(8) For selected examples on the hetero-Diels–Alder cycloadditions with 1,2,4-triazines, see: (a) Boger, D. L. *Chem. Rev.* **1986**, *86*, 781.

(b) Raw, S. A.; Taylor, R. J. K. *J. Am. Chem. Soc.* **2004**, *126*, 12260.

(c) Fernández Sainz, Y. F.; Raw, S. A.; Taylor, R. J. K. *J. Org. Chem.* **2005**, *70*, 10086. (d) Catozzi, N.; Edwards, M. G.; Raw, S. A.; Wasnaire, P.; Taylor, R. J. K. *J. Org. Chem.* **2009**, *74*, 8343. (e) Shi, B.; Lewis, W.; Campbell, I. B.; Moody, C. J. *Org. Lett.* **2009**, *11*, 3686. (f) Lorion, M.; Guillaumet, G.; Brière, J.-F.; Suzenet, F. *Org. Lett.* **2015**, *17*, 3154.

(9) (a) Rätz, R.; Schroeder, H. *J. Org. Chem.* **1958**, *23*, 1931. (b) Paudler, W. W.; Barton, J. M. *J. Org. Chem.* **1966**, *31*, 1720. (c) Neunhoeffer, H. In *Comprehensive Heterocyclic Chemistry II*; Katritzky, A. R., Rees, C. W., Scriven, E. F. V., Eds.; Pergamon: Oxford, 1996; Vol. 6, p 50. For recent applications of the method, see: (d) Zhao, Z.; Leister, W. H.; Strauss, K. A.; Wisnoski, D. D.; Lindsley, C. W. *Tetrahedron Lett.* **2003**, *44*, 1123. (e) Ernd, M.; Heuschmann, M.; Zipse, H. *Helv. Chim. Acta* **2005**, *88*, 1491. (f) Laphookhieo, S.; Jones, S.; Raw, S. A.; Fernández Sainz, Y.; Taylor, R. J. K. *Tetrahedron Lett.* **2006**, *47*, 3865. (g) Phucho, T.; Nogpiur, A.; Tumtin, S.; Nongrum, R.; Myrboh, B.; Nongkhaw, R. L. *ARKIVOC* **2008**, *xv*, 79. (h) Ghorbani-Vaghei, R.; Shahriari, A.; Salimi, Z.; Hajnazari, S. *RSC Adv.* **2015**, *5*, 3665.

(10) (a) Saraswathi, T. V.; Srinivasan, V. R. *Tetrahedron Lett.* **1971**, *12*, 2315. For recent examples, see: (b) Reference 9e. (c) Kidwai, M.; Sapra, P.; Bushan, K. R.; Misra, P. *Synth. Commun.* **2001**, *31*, 1639. (d) Kopchuk, D. S.; Khasanov, A. F.; Kovalev, I. S.; Zyryanov, G. V.; Rusinov, V. L.; Chupakhin, O. N. *Mendeleev Commun.* **2013**, *23*, 209.

(11) (a) See refs 9c, d and 10d. (b) Kopchuk, D. S.; Chepchugov, N. V.; Kim, G. A.; Zyryanov, G. V.; Kovalev, I. S.; Rusinov, V. L.; Chupakhin, O. N. *Tetrahedron Lett.* **2016**, *57*, 296.

(12) For other methods for the synthesis of 1,2,4-triazines, see: (a) Reference 8e. (b) Lukin, A.; Vedekhina, T.; Tovpeko, D.; Zhurilo, N.; Krasavin, M. *RSC Adv.* **2016**, *6*, 57956. (c) Tang, D.; Wang, J.; Wu, P.; Guo, X.; Li, J.-H.; Yang, S.; Chen, B.-H. *RSC Adv.* **2016**, *6*, 12514.

(13) Hong, D.; Lin, X.; Zhu, Y.; Lei, M.; Wang, Y. *Org. Lett.* **2009**, *11*, 5678.

(14) The acid-catalyzed *N*-alkylation of hydrazones has only been reported in two publications in the presence of alcohol substrates: (a) Reddy, C. R.; Jithender, E. *Tetrahedron Lett.* **2009**, *50*, 5633. (b) Theerthagiri, P.; Lalitha, A. *J. Iran. Chem. Soc.* **2013**, *10*, 717.

(15) From a safety issue point of view, particularly during larger scale reactions for industry, replacement of BF<sub>3</sub>·OEt<sub>2</sub> by BF<sub>3</sub>·THF was possible with no significant drop of the yield.

(16) CCDC 1526630 contains supplementary crystallographic data for compound **3b**.

(17) The trivalent boronate product formed from the *m*-Bpin-phenyl hydrazone was oxidized before isolation, these compounds being prone to decomposition via hydrolysis and/or protodeboronation during column chromatography. For the oxidation procedure, see: Yamashita, Y.; Tellis, J. C.; Molander, G. A. *Proc. Natl. Acad. Sci. U. S. A.* **2015**, *112*, 12026.

(18) (a) Yamanaka, H.; Konno, S.; Sagi, M.; Yuki, Y. *Heterocycles* **1985**, *23*, 2807. (b) Khasanov, A.; Kopchuk, D. S.; Kovalev, I. S.; Taniya, O. S.; Zyryanov, G. V.; Rusinov, V. L.; Chupakhin, O. N. *Mendeleev Commun.* **2015**, *25*, 332. (c) Utepova, I. A.; Trestsova, M. A.; Chupakhin, O. N.; Charushin, V. N.; Rempel, A. A. *Green Chem.* **2015**, *17*, 4401.

(19) For reviews on the nucleophilic ring-opening of aziridines and its regioselectivity, see: (a) Hu, X. E. *Tetrahedron* **2004**, *60*, 2701. (b) Padwa, A.; Murphree, S. S. *ARKIVOC* **2006**, *iii*, 6.